Correlation of sera TNF-α with percentage of bone marrow plasma cells, LDH, β2-microglobulin, and clinical stage in multiple myeloma

被引:46
作者
Jurisic, V [1 ]
Colovic, M [1 ]
机构
[1] Univ Kragujevac, Sch Med, Dept Pathophysiol, YU-34000 Kragujevac, Yugoslavia
关键词
multiple myeloma; TNF-alpha; lactate dehydrogenase; beta(2)-microglobulin; clinical stage;
D O I
10.1385/MO:19:3:133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor necrosis factor-alpha (TNF-alpha) is important for function, differentiation, and transformation of B-lymphocytes in multiple myeloma (MM) but can also induce apoptosis of myeloma cells. Based on this opposite effect, it is very crucial to analyze the correlation of the serum level of TNF-alpha with clinical parameters of the patients. In this article, we analyzed 18 MM patients, 48% male and 52% female, with a mean age of 52 yr (range: 35-81 yr), clinical stage I in 21.4%, stage II in 26.4%, and stage III in 52.2% of patients. Patients with advanced clinical stage, presence of osteolysis, and elevated lactate dehydrogenase (LDH) had a significant difference (Mann-Whitney U-test, p < 0.05) in the serum level of TNF-alpha in comparison with those in the early stage, without osteolysis, and normal LDH. The correlation of individual values of TNF-alpha with the percentage of plasma cells in the bone marrow, LDH, beta(2)-microglobulin, fibrinogen, and sedimentation rate was significant (p < 0.05). However, we have not found a significant correlation between TNF-alpha and concentration of hemoglobin, the number of white blood cells or platelets (p > 0.05). We concluded that our data indicate determination of TNF-alpha as a good parameter for estimation of tumor mass presence, among individual patients with MM, and may by used for monitoring during application of different therapy protocols.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 21 条
[1]   The role of human and viral cytokines in the pathogenesis of multiple myeloma [J].
Berenson, JR ;
Sjak-Shie, NN ;
Vescio, RA .
SEMINARS IN CANCER BIOLOGY, 2000, 10 (05) :383-391
[2]  
BORSET M, 1994, EUR J HAEMATOL, V53, P31
[3]  
Borset M, 1999, EUR J HAEMATOL, V63, P345
[4]   High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment [J].
Davies, FE ;
Rollinson, SJ ;
Rawstron, AC ;
Roman, E ;
Richards, S ;
Drayson, M ;
Child, JA ;
Morgan, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) :2843-2851
[5]   A QUICK AND SIMPLE METHOD FOR THE QUANTITATION OF LACTATE-DEHYDROGENASE RELEASE IN MEASUREMENTS OF CELLULAR CYTO-TOXICITY AND TUMOR NECROSIS FACTOR (TNF) ACTIVITY [J].
DECKER, T ;
LOHMANNMATTHES, ML .
JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 115 (01) :61-69
[6]  
Desser L, 1997, INT J IMMUNOTHER, V13, P121
[7]   Interleukin 6, tumour necrosis factor α and lymphotoxin polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma [J].
Dring, AM ;
Davies, FE ;
Rollinson, SJ ;
Roddam, PL ;
Rawstron, AC ;
Child, JA ;
Jack, AS ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :249-250
[8]   Increased T cell cytotoxicity by Betathine™-induced upregulation of TNFα [J].
Dunn, TM ;
Wormsley, S ;
Taub, FE ;
Pontzer, CH .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 2000, 22 (03) :213-227
[9]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[10]  
2-U